Jordan Hale: Can I confess something slightly embarrassing before we start?
Alex Mercer: Always, yeah.
Jordan Hale: I think I've been wrong about placebos my whole life. Like, not wrong in a small way — wrong about what they are and why anyone should care. I assumed it was basically a medical parlor trick. And then I hit this number and just stopped.
Alex Mercer: What number?
Jordan Hale: Sixty to eighty percent pain reduction from an inert pill. Same ballpark as actual medication in a lot of studies. And I thought — okay, if that's real, and it is real, then the question of how it works isn't a philosophical curiosity, it's, like, a genuine scientific emergency almost.
Alex Mercer: I think the field would've agreed with you — up until 2024, they had what seemed like a solid answer. Dopamine. Expectation activates dopamine release, dopamine modulates pain experience. Clean mechanism.
Jordan Hale: Until Kunkel et al. in PLoS Biology just... dismantled it. They used frequentist and Bayesian analysis and found strong evidence against a direct causal dopaminergic role in placebo analgesia. Which, I mean — that's a decade of confident storytelling coming apart.
Alex Mercer: Right — but the part that doesn't fit is how little attention that revision got outside research circles. The dopamine narrative kept circulating.
Jordan Hale: So what does the current framework say? Because expectancy keeps coming up — this idea that a conscious or unconscious predictive belief about a future outcome is actually doing the work, not a specific neurotransmitter.
Alex Mercer: Expectancy is the leading frame, basically. And the pathway is physical — descending pain inhibitory circuits run from cortex down through the brainstem, suppress incoming pain signals at the spinal cord. Top-down. A belief, acting on tissue.
Jordan Hale: And the nocebo effect proves it's not just optimism doing something vague — negative expectations worsen outcomes through those same pathways. Pain up, symptoms worse. The same circuitry running in reverse.
Alex Mercer: Which lands us somewhere genuinely uncomfortable: we can measure sixty to eighty percent pain reduction, we can trace the neural architecture, and we still can't say with confidence what's actually pulling the lever. So what do we know?
Jordan Hale: What we know is that the circuit is real. Like, an actual physical thing — your brain has a volume knob for pain, and expecting relief can literally turn it down. That's not a metaphor. Bracing yourself before jumping into cold water, the way it's almost more bearable when you know it's coming? Same mechanism.
Alex Mercer: That expectation is a signal. Sent downward.
Jordan Hale: Which — okay, when you say it like that it sounds almost mundane, but the anatomy of it is wild. The medial prefrontal cortex and the anterior cingulate cortex are projecting down to the brainstem — to this region called the ventrolateral periaqueductal gray, the vlPAG — and that region gates pain signals before they even finish climbing the spinal cord.
Alex Mercer: And here's what Livrizzi et al. actually showed in Neuron in 2026 — they reverse-translated a human placebo paradigm into mice, causally identified that cortex-to-vlPAG circuit, and found something genuinely specific: cortical inputs to the vlPAG are required for placebo analgesia but not for morphine analgesia.
Jordan Hale: Wait — morphine doesn't need the cortex?
Alex Mercer: Morphine works on the vlPAG directly. Expectation has to come from above — the prefrontal cortex has to send the signal down. So the cognitive piece isn't just context, it's load-bearing.
Jordan Hale: So picture a post-surgical patient in a hospital bed, and a nurse walks in and spends, like, thirty seconds explaining that the next injection will significantly reduce the pain — that conversation, that thirty-second human interaction, is activating a descending circuit from her prefrontal cortex through the brainstem before the drug has even metabolized. The expectation is doing mechanistic work the drug doesn't need to do.
Alex Mercer: That's the right image. And the vlPAG isn't just a relay — conditioning potentiates endogenous opioid release there. The brain is literally manufacturing its own analgesia at that site.
Jordan Hale: Which means it's not just — wait, no, I want to make sure I have this right — it's not just suppressing the signal, it's actively producing a chemical response.
Alex Mercer: Both. And Zeidan et al. from 2015 in the Journal of Neuroscience helped nail down that this isn't just general relaxation doing the work — mindfulness meditation and placebo analgesia operate through distinct neural mechanisms. Placebo has its own signature. You can't explain it away as 'the patient calmed down.'
Jordan Hale: That distinction matters so much, you know, because that's the move people make — 'oh, they just relaxed.' But the circuits are different.
Alex Mercer: Basically. The biology is specific, the pathway is traceable, the effect is measurable. Which makes the dopamine question actually stranger — if you have this clean cortex-to-brainstem circuit doing real work, where does dopamine even enter the picture?
Jordan Hale: That's exactly the problem. Because for a decade the field was confidently pointing to dopamine, and then 2024 shows up with Kunkel in PLoS Biology and says — strong Bayesian and frequentist evidence against a direct causal role. So the circuit exists, the effect is real, and the neurochemistry we thought we understood is... not settled.
Alex Mercer: And that's what makes the Kunkel result genuinely disorienting — it's not that dopamine is irrelevant to the brain, it's that the specific causal story, expectation triggers dopamine release, and dopamine drives the analgesia, that whole chain, Kunkel runs the frequentist and Bayesian tests and both come back against it. Not ambiguous. Strong evidence against.
Jordan Hale: Both methods pointing the same direction — that's not a soft finding.
Alex Mercer: No. And the uncomfortable part is — the dopamine story was compelling because it was mechanistically satisfying. It connected expectation to a known neurotransmitter to a known outcome. That's the shape of a good explanation. But the shape isn't the evidence.
Jordan Hale: Which is — okay, that's the part that kind of unnerves me, you know? Like, if the field spent a decade being confident about dopamine because the story had the right shape, what else in the placebo literature is being held up by narrative rather than data? And I don't mean that in a cynical way, I mean it genuinely — how do we know where the solid ground is?
Alex Mercer: I think the endogenous opioid piece is actually on firmer footing. The vlPAG conditioning result from Livrizzi — that conditioning potentiates the brain's own opioid release at that specific site — that's a causal identification, not a correlation.
Jordan Hale: So the opioid system steps in where the dopamine story collapsed.
Alex Mercer: To some extent. But — and this is where I want to be careful — the exact pathways beyond that cortex-vlPAG-opioid circuit are still genuinely contested. Sources in this space treat them as established in one sentence and acknowledge their uncertain status two paragraphs later. The field hasn't fully resolved that.
Jordan Hale: Wait, so even the replacement story has gaps?
Alex Mercer: Yeah. Which brings up the placebome, actually — and this one I find genuinely strange. There's a heritable genetic component to placebo responsiveness. Variants in dopamine and serotonin signaling systems that predict how placebo-responsive a given person's brain is. So dopamine genetics still matter — just not through the mechanism anyone thought.
Jordan Hale: Hold on. Heritable? Like, some people are biologically wired from birth to get more out of a placebo — not because they believe harder, but because of their actual genome?
Alex Mercer: That's basically what the placebome research says. Which means the 'positive thinking heals you' framing is — I mean, it's not wrong exactly, it's just radically incomplete. Your responsiveness is partly upstream of your beliefs.
Jordan Hale: And that's going to matter even more once we get into why open-label placebos work at all — because if belief isn't fully running the show, something else is driving it, and that's the part that I think genuinely reframes everything.
Alex Mercer: And that's exactly the puzzle the open-label placebo research tears open — because if the mechanism were just conscious expectation, telling someone 'this pill is inert' should kill the effect entirely. But it doesn't.
Jordan Hale: Wait, it genuinely still works? Like, measurably?
Alex Mercer: Measurable symptom relief, yes. Which means conscious predictive belief cannot be the sole driver. Something else is operating below that level.
Jordan Hale: So how do you have expectation without — I mean, that's the thing, right? The expectancy framework is supposed to be the dominant account, and here's a finding that just... doesn't fit inside it neatly.
Alex Mercer: Classical conditioning. That's the answer, I think. Prior treatment experiences — the smell of a clinic, swallowing a pill, a practitioner's warmth — those cues have been paired with physiological relief often enough that the cue alone can trigger the response. No conscious belief required.
Jordan Hale: Like Pavlov, but your brainstem is the dog.
Alex Mercer: Basically. And the Livrizzi 2026 paper is where this gets specific — conditioning potentiates noxious-stimulus-evoked endogenous opioid release in the vlPAG. That's below the level of conscious access. You're not believing your way to opioid release. The cue does it.
Jordan Hale: That's — okay, that's the 'oh, that's why' moment for me. The ritual of the pill, the white coat, the clinical setting — that whole apparatus is literally a conditioned stimulus that bypasses what you consciously think is happening.
Alex Mercer: Which complicates the expectancy framework considerably. It might be partially a convenient narrative — tidy, cognitive, something we can describe to a patient. But part of the mechanism is running on tracks that conscious belief can't even access.
Jordan Hale: So where does this conditioning actually have leverage? Because I'm now wondering — you know, pain obviously, but what else?
Alex Mercer: That's the spectrum question. Pain, nausea, fatigue, mood — enormous effects. Top-down cortical pathways can gate what gets perceived. Bacterial infection clearance? Essentially nothing. You can't condition your way to synthesizing antibiotics. The vlPAG circuit has no lever there.
Jordan Hale: And then there's the middle — inflammatory markers, cytokines in depression. Real, measurable shifts, but whether they're clinically meaningful is genuinely... I mean, nobody seems to have a firm answer on that boundary.
Alex Mercer: That's the honest state of it. The effect on cytokines is real enough to matter to a suffering patient, uncertain enough that confident clinical prescription isn't licensed. Statistically measurable and clinically meaningful are not the same line, and right now the literature hasn't drawn it.
Jordan Hale: And that's the part I keep — no, wait, that's the part that stops me. Because you can't draw the clinical line until you understand the mechanism, and we just spent, like, forty minutes establishing that the mechanism is actively being revised. So on what evidence does a doctor start prescribing placebos at scale? The field hasn't established thresholds — no agreed effect size, no clear condition specificity, no patient population criteria. Clinical recommendations are running ahead of mechanistic consensus.
Alex Mercer: And that's the fragility that the Kunkel result exposed. Every clinical framework that was built on the dopamine story inherits that instability. If you told patients 'this works because expectation activates dopamine release' — and some practitioners did — what happens in five years when the explanation shifts again?
Jordan Hale: Patient trust. Which is — I mean, nobody's quantifying that. The field doesn't have a measure for what happens to the therapeutic relationship when the mechanistic story the doctor gave you turns out to be wrong. That cost is real and it's just... sitting there, unmeasured.
Alex Mercer: Which is why I think the most defensible clinical move isn't inert pills. It's optimizing what's already there — practitioner warmth, verbal suggestion, the clinical setting itself. Those contextual and ritual factors amplify placebo responses, they're embedded in good care anyway, and deploying them doesn't require any mechanistic certainty or any deception.
Jordan Hale: Right — and no one has to explain the dopamine story to a patient if there's no dopamine story being told.
Alex Mercer: Basically. The placebome complicates it further — some people's serotonin and dopamine genetics make them more responsive before any ritual even starts. You can't optimize your way around that. But the contextual factors are at least in a practitioner's hands.
Jordan Hale: You know, we started this whole thing because I hit that sixty-to-eighty percent number and thought it was a parlor trick. And now I'm landing somewhere where the trick isn't the pill — the trick is the room, the warmth, the thirty-second conversation before the injection. Which is... I don't know, that's either very mundane or kind of beautiful depending on the day.
Alex Mercer: A thought traveling down your spinal cord. Still don't fully know why. That's a fair place to stop.
